Join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and process efficiency from preclinical to commercial. Get an overview of our integrated CTDMO offering, our newly launched mRNA Center of Excellence for robust mRNA manufacturing, and our services for analytical development and product characterization.

In this technical symposium, industry experts are presenting about:

  • Key factors for a robust mRNA manufacturing through next-generation PCR-based workflow
  • Analytical development and product characterization for mRNA vaccines and therapeutics
  • Improving the performance of self-replicating RNA

Duration:1hr 30m

Want to learn more? Watch Now.

Chief Development Officer

Dr. Andrew Geall is Replicate Bioscience's Chief Development Officer and co-founder. With over 20 years of experience in developing drug delivery systems, he is a pioneer in mRNA vaccines and nucleic acid delivery. He holds 505 patent applications and 203 issued patents in multiple jurisdictions.

Before Replicate, he served as Chief Scientific Officer at Precision NanoSystems Inc., where he worked on creating nanoparticle medicines using LNP delivery systems and microfluidic formulation platform. He also held positions at Avidity Biosciences and Novartis, where he led the development of mRNA vaccines platform and led the Global siRNA Formulation Team. Dr. Geall obtained his pharmacy degree and a PhD from the University of Bath in the UK.

Strategy Manager, Emerging Modalities

Conner is the strategy manager for emerging modalities. He is responsible for the strategy development and positioning of the mRNA analytical development and biosafety testing portfolio.

He holds a B.S. in genetics from the University of Wisconsin-Madison and an MBA in strategy and leadership from Indiana University Kelley School of Business.

Global Business Lead, Product Characterization

Jay Sterling is the Global Business Lead, Product Characterization. Jay’s main area of expertise is in the development of physiochemical methods designed to measure the critical quality attributes of drug products, including monoclonal antibodies, vaccines, nanoparticles, and gene therapy delivery vectors. Previously. he worked at a variety of small biotechnology, large pharmaceutical, and contract research companies (including Biolex Tx, GSK Vaccines, and Catalent). Jay received his Ph.D. in biochemistry and molecular biology from the University of Georgia.

Head of Operations

Bastian Rouven Brückner is the Head of Operations at our mRNA production site in Hamburg. Bastian’s main area of expertise is the mRNA production based on a PCR workflow. He was responsible for the establishment of a new GMP facility for mRNA production at mid-scale.

Before joining AmpTec GmbH (a subsidiary of

Merck KGaA, Darmstadt, Germany
), he demonstrated broad expertise in cell biophysics and molecular biology by publishing in several peer-reviewed journals. Bastian holds an M.Sc with distinction in chemistry and a Ph.D. in biophysical chemistry from Goettingen University.

Associate Director, Head of mRNA Process & Delivery

Aditi Mehta heads the mRNA Process & Delivery labs at

Merck KGaA, Darmstadt, Germany
. In this role, she is mainly responsible for the development of novel, innovative solutions for mRNA synthesis – at various scales – and the development of state-of-the-art excipients for mRNA delivery.

Before joining

Merck KGaA, Darmstadt, Germany
in 2020, Aditi worked as a postdoc and group leader at the Department of Pharmaceutical Technology, Ludwig Maximilians University of Munich, focusing on pulmonary delivery of nucleic acids.

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

The views and opinions expressed in this blog / article are those of the authors and do not…

Scroll to Top